🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,522 results for “solution” Clear

  1. ABBV-RGX-314 or RGX-314, ABBV-RGX-314 or RGX-314, Lucentis 10 mg/ml solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe

    AbbVie Deutschland GmbH & Co. KG

    Neovascular age-related macular degeneration

    phase 3 small molecule active

    1 trial

  2. ABIRATERONE ACETATE, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, SYLVANT 400 mg powder for concentrate for solution for infusion, CABAZITAXEL, AMG 509, ABIRATERONE ACETATE, DOCETAXEL

    Amgen

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  3. ABIRATERONE ACETATE, ABIRATERONE ACETATE, ENZALUTAMIDE, ABIRATERONE ACETATE, Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation, ENZALUTAMIDE, ENZALUTAMIDE

    Novartis Pharmaceuticals

    PSMA-positive metastatic castration-resistant prostate cancer

    phase 3 small molecule active

    1 trial

  4. ABIRATERONE ACETATE, DAROLUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, APALUTAMIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion, ENZALUTAMIDE

    Ningbo Cancer Hospital

    Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)

    phase 3 small molecule active

    1 trial

  5. ACICLOVIR VIATRIS 500 mg, poudre pour solution injectable (I.V.), CHLORURE DE SODIUM 0,9 % B. BRAUN, solution injectable en ampoule

    Pari Pharma GmbH

    Patients in ICU with invasive mechanical ventilation and HSV throat reactivation with 1 or no organ failures.

    phase 3 small molecule active

    1 trial

  6. ACTILYSE 50mg placebo, ACTILYSE, poudre et solvant pour solution injectable et perfusion

    Pari Pharma GmbH

    intermediate-high-risk acute pulmonary embolism

    phase 3 small molecule active

    1 trial

  7. ACTILYSE, poudre et solvant pour solution injectable et perfusion, ACTILYSE, poudre et solvant pour solution injectable et perfusion, Metalyse 10,000 units powder and solvent for solution for injection, ACTILYSE, poudre et solvant pour solution injectable et perfusion, Metalyse 5 000 units (25 mg) powder for solution for injection

    Tour Hekla

    Acute ischaemic stroke due to basilar artery occlusion.

    phase 3 small molecule active

    1 trial

  8. ACTISOUFRE, solution pour pulvérisation nasale/buccale en flacon pressurisé, Actisoufre Placebo

    Laboratoire HRA Pharma

    rhinosinusitis not requiring antibiotic therapy, rhinopharyngitis not requiring antibiotic therapy, Acute rhinitis not requiring antibiotic therapy

    phase 3 small molecule active

    1 trial

  9. ADRENALINE AGUETTANT 1 mg/ml, solution injectable en ampoule

    Novo Nordisk A/S

    Cardiorespiratory arrest at birth in full-term newborns

    phase 3 small molecule active

    1 trial

  10. ADVATE 500 IU powder and solvent for solution for injection., VEYVONDI 1300 IU powder and solvent for solution for injection., ADVATE 1000 IU powder and solvent for solution for injection., VEYVONDI 650 IU powder and solvent for solution for injection.

    Takeda

    severe von Willebrand Disease

    phase 3 small molecule active

    1 trial

  11. ADX-102 Ophthalmic Solution (0.5%)

    Aldeyra Therapeutics

    Non-infectious Anterior Uveitis

    phase 3 small molecule completed

    1 trial

  12. ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Pembrolizumab, KEYTRUDA 25 mg/m

    Celltrion Healthcare Australia Pty Ltd

    Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  13. ALN-TTRSC04, Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam Netherlands B.V.

    Hereditary transthyretin-mediated amyloidosis with polyneuropathy

    phase 3 small molecule active

    1 trial

  14. ALTUVOCT 2 000 IU powder and solvent for solution for injection, ALTUVOCT 3 000 IU powder and solvent for solution for injection, ALTUVOCT 4 000 IU powder and solvent for solution for injection, ALTUVOCT 250 IU powder and solvent for solution for injection, ALTUVOCT 1 000 IU powder and solvent for solution for injection, ALTUVOCT 500 IU powder and solvent for solution for injection

    Swedish Orphan Biovitrum AB (publ)

    Haemophilia A

    phase 3 small molecule active

    1 trial

  15. ALXN1850, Strensiq 40 mg/ml Solution for Injection, Strensiq 100 mg/ml Solution for Injection

    Alexion Europe SAS

    Hypophosphatasia

    phase 3 small molecule active

    1 trial

  16. AMIKACINE VIATRIS 1 g, poudre pour solution injectable en flacon, CHLORURE DE SODIUM 0,9 % COOPER, solution pour perfusion

    Tour Hekla

    Patients with ventilator-associated tracheobronchitis

    phase 3 small molecule active

    1 trial

  17. AMOXICILLINE/ACIDE CLAVULANIQUE PANPHARMA 2 g/200 mg ADULTES, poudre pour solution injectable

    Pari Pharma GmbH

    Intensive care, Ventilator Associated Pneumonia

    phase 3 small molecule active

    1 trial

  18. ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion, Vyvgart 1 000 mg solution for injection

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  19. ATENATIV 50 UI/mL, poudre et solvant pour solution pour perfusion, Atenativ 1000 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Atenativ 1000 UI/20 ml polvere e solvente per soluzione per infusione endovenosa, Atenativ 50 NE/ml por és oldószer oldatos infúzióhoz vagy injekcióhoz, ATENATIV 1000 U.I., polvo y disolvente para solución para perfusión

    Lacuna Pharma Pty Ltd

    Congenital antithrombin deficiency

    phase 3 small molecule active

    1 trial

  20. AZD0120, Bortezomib Hikma 3,5 mg Pulver zur Herstellung einer Injektionslösung, DARZALEX 1800 mg solution for injection, Dexamethason 1,5 mg JENAPHARM®, Kyprolis 10 mg powder for solution for infusion, Dexamethason 0,5 mg JENAPHARM®, Pomalidomide Zentiva 3 mg hard capsules, Pomalidomide Zentiva 2 mg hard capsules, Dexamethason 4 mg JENAPHARM, Kyprolis 30 mg powder for solution for infusion, Pomalidomide Zentiva 1 mg hard capsules, Pomalidomide Zentiva 4 mg hard capsules, Kyprolis 60 mg powder for solution f

    AstraZeneca AB

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  21. Abraxane 5 mg/ml powder for dispersion for infusion., Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, Fluorouracil Accord 50 mg/ml šķīdums injekcijām vai infūzijām, CALCIUM FOLINATE , GEMCITABINE ACCORD 100 mg/ml, solution à diluer pour perfusion, Oxaliplatin Accord 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Ipsen

    Metastatic Pancreatic Adenocarcinoma

    phase 3 small molecule active

    1 trial

  22. Abraxane 5 mg/ml powder for dispersion for infusion., Paclitaxel 6 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Gemcitabine 38 mg/mL concentrate for solution for infusion

    Gilead Sciences Pty Limited

    PD-L1-negative metastatic triple-negative breast cancer or PD-L1-positive metastatic triple-negative breast cancer previously treated with an anti-PD-(L)1 agent in the curative setting

    phase 3 small molecule active

    1 trial

  23. Aceclidine+Brimonidine combination ophthalmic solution

    LENZ Therapeutics

    Presbyopia

    phase 3 small molecule completed

    6 trials

  24. Adtralza 150 mg solution for injection in pre-filled syringe, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP.

    LEO Pharma A/S

    Treatment of moderate-to-severe Atopic dermatitis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources